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The compound 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD or dioxin), the most toxic
halogenated aromatic hydrocarbon (1), is a
ubiquitous contaminant of various industrial
and combustion processes, including med-
ical waste incineration. Dioxin is classiﬁed as
a known human carcinogen (1), and concern
about the reproductive toxicity of dioxin has
been growing (2). Partially because of this
concern, the U.S. Environmental Protection
Agency and the World Health Organization
have conducted a reassessment of dioxin,
including human health consequences (3,4).
In the past decade, several animal studies
have suggested that prenatal and postnatal
exposure to dioxin and dioxin-like chemicals
may profoundly affect the reproductive sys-
tems of both male and female animals perhaps
via endocrine disruption (2). Some articles
have concluded that dioxin-like compounds
may be responsible for the failure of certain
animal species to reproduce (5) and for a
decrease in human sperm count (6). Another
publication has noted high frequencies of
endometriosis among infertile women living
in Belgium, where breast milk concentrations
of dioxin are among the highest in the world
(7). The etiology of endometriosis is unknown
(8). An association of dioxin with endometrio-
sis is of public health signiﬁcance because the
estimated prevalence of endometriosis ranges
from 1 to 10% in women of reproductive age
(8) and because endometriosis is associated
with signiﬁcant costs for hospitalization and
workdays lost (8).
Experimental animal evidence supports
the association of endometriosis and expo-
sure to dioxin-like chemicals. In 1993, Rier
et al. (9) reported a dose–response relation
between TCDD levels (5 and 25 ppt) in
feed and the incidence and severity of
endometriosis in 6- to 10-year-old adult
rhesus monkeys, diagnosed a decade after
dosing ceased. TCDD has also promoted
the survival and growth of surgically
induced endometrial implants in nonhuman
primates (10) and in mice (11–13), but not
in rats (12). More recent animal data sug-
gest that endometriosis may also be associ-
ated with increased body burden of
dioxin-like polychlorinated biphenyls
(PCBs), particularly PCB 77 and PCB 126,
and of total serum TCDD toxic equivalents
(TEQ) (14).
The animal studies have stimulated a
series of hospital-based endometriosis
case–control studies in humans, with incon-
sistent results. A German study (15) found
higher serum levels of three non-dioxin–like
PCB congeners (PCBs 138, 153, 180) in
cases than in controls. An Israeli study (16)
reported low-levels of TCDD in 8 of the 44
cases (18%; range = 0.7–1.2 ppt) but in only
1 of the 35 (2%) controls (0.4 ppt), yielding
a nonsigniﬁcant odds ratio of 7.6. Using the
CALUX assay, a Belgian study (17) reported
a high TEQ (> 100 pg/g) in 6 of 42 cases
(14%) but in only 1 of 27 controls (4%), for
a nonsigniﬁcant crude odds ratio of 4.3 [95%
confidence interval (CI) = 0.49–43.6).
Studies in the United States (18) and Canada
(19) found no association between human
levels of selected environmental chemicals
and endometriosis. The U.S. study measured
TCDD and 21 other polychlorinated
dibenzo-p-dioxins (PCDDs), polychlorinated
dibenzofurans (PCDFs), and PCB congeners,
but had a small sample size (15 cases and geo-
graphically matched controls). However, the
Canadian study, the largest study of all (86
cases and 70 controls), found no differences
between levels in cases and controls when
measuring 14 noncoplanar and coplanar PCB
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Articles
Dioxin, a ubiquitous contaminant of industrial combustion processes including medical waste
incineration, has been implicated in the etiology of endometriosis in animals. We sought to deter-
mine whether dioxin exposure is associated with endometriosis in humans. We conducted a pop-
ulation-based historical cohort study 20 years after the 1976 factory explosion in Seveso, Italy,
which resulted in the highest known population exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD). Participants were 601 female residents of the Seveso area who were ≤ 30 years old in
1976 and had adequate stored sera. Endometriosis disease status was deﬁned by pelvic surgery,
current transvaginal ultrasound, pelvic examination, and interview (for history of infertility and
pelvic pain). “Cases” were women who had surgically conﬁrmed disease or an ultrasound consis-
tent with endometriosis. “Nondiseased” women had surgery with no evidence of endometriosis or
no signs or symptoms. Other women had uncertain status. To assess TCDD exposure, individual
levels of TCDD were measured in stored sera collected soon after the accident. We identiﬁed 19
women with endometriosis and 277 nondiseased women. The relative risk ratios (RRRs) for
women with serum TCDD levels of 20.1–100 ppt and >100 ppt were 1.2 [90% conﬁdence inter-
val (CI) = 0.3–4.5] and 2.1 (90% CI = 0.5–8.0), respectively, relative to women with TCDD lev-
els ≤ 20 ppt. Tests for trend using the above exposure categories and continuous log TCDD were
nonsigniﬁcant. In conclusion, we report a doubled, nonsigniﬁcant risk for endometriosis among
women with serum TCDD levels of 100 ppt or higher, but no clear dose response. Unavoidable
disease misclassiﬁcation in a population-based study may have led to an underestimate of the true
risk of endometriosis. Key words: dioxin, endometriosis, environmental exposures, epidemiology.
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sured in the positive German study) and 11
chlorinated pesticides; they did not measure
TCDD or other dioxins or furans. No studies
specifically measured the dioxin-like PCB
congeners found to be related to endometrio-
sis in Rier et al.’s study (14). In general, small
sample size and/or a failure to evaluate expo-
sure to dioxins or other dioxin-like com-
pounds limited most of these studies.
If a relationship exists between dioxin
and endometriosis, it should be most appar-
ent in a highly exposed population. In 1976,
an explosion at a chemical factory near
Seveso, Italy, resulted in the highest TCDD
levels known in human residential popula-
tions (20). Bois and Eskenazi (21) con-
ducted a toxicokinetic analysis of the TCDD
levels in serum collected at the time of the
explosion for 19 of the most heavily exposed
residents of Seveso (9,21). They took into
account the differences in dose and timing
between the residents and the monkeys in
the study by Rier et al. (9). In all cases the
estimates from the area under the time–con-
centration curve exceeded the values for the
monkeys receiving the higher dose (25 ppt).
Thus, if humans are as sensitive as rhesus
monkeys, the TCDD exposure levels in the
Seveso cohort should be sufficient to result
in endometriosis (21).
Twenty years after the accident, we con-
ducted the Seveso Women’s Health Study
(SWHS). The primary goal was to deter-
mine if there was an association between
TCDD exposure and endometriosis among
women of reproductive age who had resided
in the exposed area. Serum samples collected
soon after the accident and analyzed for this
study made it possible to quantify individual
TCDD levels (22).
Methods
The Seveso accident. About noon on 10 July
1976, an explosion occurred in the ICMESA
chemical plant near Seveso, Italy, approxi-
mately 25 km north of Milan. Up to 30 kg
of TCDD were deposited over an area of
about 18 km2 (23). The area around the
plant site was divided into zones based on
soil levels of TCDD. Zone A, the most
heavily contaminated area, housed 736 resi-
dents, all of whom were evacuated within 2
weeks after the accident. Zone B, the area of
next greatest contamination, housed almost
4,500 residents who were not evacuated but
warned about consuming locally grown
food. Zone R, the least contaminated area,
housed about 35,000 residents who were
neither warned nor evacuated (24). A nonex-
posed area was delineated as zone non-ABR
and encompassed the surrounding region of
180,000 inhabitants. As part of a health
assessment, a blood sample was collected
soon after the explosion for clinical chem-
istry tests; the remaining portion of the
serum was stored for future studies (20).
Initial analyses of this population revealed
that the population was highly exposed to
TCDD, but not to PCDDs or PCDFs (22);
PCB congeners were not measured.
Study population. Women eligible for
SWHS were 30 years old or younger in
1976, had adequate stored sera that had
been collected between 1976 and 1980, and
had resided at the time of the accident in
zones A or B. A total of 953 women met
these criteria. Twelve women could not be
located or reached, seven had died, and nine
were too ill to participate. Of the remaining
925 women, 751 (81%) agreed to partici-
pate. We excluded 54 virgins, 3 women with
Turner’s syndrome, and 93 women who
refused the examination or ultrasound. This
left 601 participants, who were similar to the
eligible women in age and zone of residence. 
Procedure. Study participation included
obtaining informed consent, drawing blood,
conducting a detailed interview, and per-
forming a gynecologic examination and a
transvaginal ultrasound. Each woman was
interviewed by a trained nurse-interviewer,
who was blinded to the woman’s serum
TCDD level and zone of residence. The
structured interview covered sociodemo-
graphic information, personal habits, and
work and medical history. The women were
specifically asked whether they had experi-
enced pelvic pain other than during their
periods, deep pain with intercourse (dyspare-
unia), and menstrual cramps (dysmenor-
rhea). They were asked to rate the pain as
mild, moderate, or severe with operational
deﬁnitions provided as below: 
• Pelvic pain: mild—occasional pelvic dis-
comfort; moderate—noticeable discomfort
for most of the cycle; severe—requires
strong analgesics, persistent pain during
cycle other than during menstruation. 
• Dyspareunia: mild—tolerated discomfort;
moderate—intercourse painful to the point
of causing interruption; severe—avoids
intercourse because of pain. 
• Dysmenorrhea: mild—some loss of work
efficiency; moderate—in bed part of the
day, occasional loss of work; severe—in
bed one or more days, incapacitation. 
Women were also asked to rate the level
of dysmenorrhea, pelvic pain, or dyspareunia
on a 10-cm line, where the left end indicated
“no pain” and the right end indicated
“unbearable pain.” In addition, women were
asked whether they had ever tried for a year
or more to get pregnant; that is, whether
they did not do anything to prevent preg-
nancy for a year or more and did not get
pregnant (infertility). We gathered detailed
information about their gynecologic and
reproductive histories. Medical records were
requested for all gynecologic conditions, dis-
eases, or procedures as well as for chronic
diseases. Medical records were abstracted
onto a form and coded by International
Classification of Diseases (25) codes by a
gynecologic nurse. 
Gynecologists at the University of
Milan, Mangiagalli Hospital, and at the
Desio Hospital conducted the examinations.
The ultrasounds were conducted both
abdominally and transvaginally. Ultrasounds
were recorded on videotape, and pho-
tographs were taken of ovaries and of any
pathologic tissue. 
Diagnostic process. The only definitive
method for diagnosis of endometriosis is
abdominal surgery. We conducted a validation
study in a clinic-based population in parallel
with this study that indicated that symptoms
or signs were not good predictors of disease,
but that ultrasound had excellent speciﬁcity
and sensitivity for ovarian endometriosis (26).
Thus, a woman was considered a “case” only if
she had endometriosis noted on a laparoscopy
or laparotomy or if she had a positive ultra-
sound (one in which a cyst or mass character-
istic of endometriosis was noted, i.e., thick
walls, regular margins, and homogeneous low
echogenicity of ﬂuid) (27). 
Before surgical findings, findings on
ultrasound and signs and symptoms were
used to divide the remaining women into
two groups: “nondiseased” or “uncertain”
for disease status. A woman was considered
nondiseased if she had surgery without a
ﬁnding of endometriosis or if she had a neg-
ative ultrasound, exam, and symptom his-
tory. A woman who had surgery in the past
(after 1976) could be considered nondis-
eased if she had no report of endometriosis
at surgery, no subsequent increase in inten-
sity of symptoms in the years after surgery,
and no physical signs at the study’s examina-
tion that would indicate the development of
endometriosis after surgery. Signs of a
positive exam included painful nodules,
uterosacral ligament scarring, pain at the
pouch of Douglas, Douglas nodularity,
vaginal lesions/endometriotic lesions,
painful/ﬁxed adnexal masses, or ﬁxed uterus.
A positive symptom history included a
report of infertility, a verbal report of mod-
erate or severe pelvic pain, dysmenorrhea, or
dyspareunia; or a pain rating in the right half
of a 10-cm line for dysmenorrhea, pelvic
pain, or dyspareunia. A woman was consid-
ered uncertain for disease if she had no
surgery and a negative ultrasound, but she
had signs on exam and/or reported symp-
toms. In some statistical analyses, women
with only signs or symptoms were considered
nondiseased based on the validation study
that suggested that only a small percentage of
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laparoscopy (26).
If any abnormality was noted on ultra-
sound, repeat ultrasound was offered.
Laparoscopy was offered to women who had
an ovarian cyst or mass noted on ultrasound;
current severe dysmenorrhea, pelvic pain, or
dyspareunia; or unexplained infertility in
women younger than 40 years old. All
laparoscopies were videotaped; lesions were
excised, if possible, and sent for histologic
evaluation. 
The examining gynecologist assigned
disease status. The consultant gynecologist
independently reviewed the study materials.
Those responsible for diagnosis were blind
to the woman’s exposure (zone or TCDD
level).
Laboratory analyses. We preferentially
selected the earliest serum sample available
and sent the samples from Desio to the U.S.
Centers for Disease Control and Prevention
(CDC) for TCDD analysis by high-resolu-
tion mass spectrometry methods (28).
Values were reported on a lipid-weight basis
in parts per trillion (29).
TCDD was measured in sera collected
between 1976 and 1977 for 559 women
(93%), between 1978 and 1981 for 25
women (4%), and in 1996 for 17 women
(3%) whose earlier samples had insufficient
volume. For women with post-1977 TCDD
values that were detectable but ≤ 10 ppt (n =
4), the measured value was used. For women
with post-1977 TCDD levels > 10 ppt, the
TCDD exposure level was back-extrapolated
to 1976 using the Filser model (30) for
women ≤ 16 years old in 1976 (n = 16) and
using a first-order kinetic model for older
women (n = 14) (31). For nondetectable
values (n = 77), one-half the detection limit
was assigned (32). For the study median
serum sample weight of 0.65 g, the median
limit of detection was 18.8 ppt, lipid
adjusted. Because of the small volume of
serum, it was not possible to measure other
PCDDs, PCDFs, or PCBs and to still main-
tain a relatively low limit of detection for
TCDD, the known exposure.
Statistical analyses. We modeled serum
TCDD both as a continuous (log TCDD)
and a categorical variable. We chose cate-
gories of ≤ 20.0 ppt, 20.1–00 ppt, and > 100
ppt. We chose 20 ppt (body burden ~4
ng/kg) as the lower limit, because the
median value was between 15 and 20 ppt for
11 pooled serum samples collected from
women residing in an unexposed area (zone
non-ABR) at the time of the accident (33).
We chose the 100 ppt limit (body burden
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Table 1. Serum TCDD levels and endometriosis disease status by select characteristics of study participants, SWHS, Italy 1996–1998.
Median TCDD (Q1–Q3)a No. (%)
Characteristics (ppt) Total Cases Uncertain Nondiseased
Zone of residence at accident
A 257.0 (114.0–713.0) 97 (16) 2 (2) 50 (52) 45 (46)
B 47.0 (22.5–220.0) 504 (84) 17 (3) 255 (51) 232 (46)
Age at follow-up (years)
20–29 166.5 (56.2–286.5) 120 (20) 5 (4) 67 (56) 48 (40)
30–39 52.2 (24.4–121.5) 236 (39) 4 (2) 126 (53) 106 (45)
≥ 40 44.0 (22.0–92.2) 245 (41) 10 (4) 112 (46) 123 (50)
Education
< Elementary 43.7 (22.0–105.0) 141 (23) 6 (4) 60 (43) 75 (53)
Required 54.3 (24.4–131.0) 135 (22) 3 (2) 72 (53) 60 (44)
Intermediate professional 62.8 (33.2–171.0) 197 (33) 7 (4) 102 (52) 88 (45)
> Secondary school 59.0 (26.6–207.5) 128 (21) 3 (2) 71 (55) 54 (42)
Marital status
Never married 148.0 (46.9–268.0) 95 (16) 2 (2) 52 (55) 41 (43)
Ever married 49.5 (23.5–123.0) 506 (84) 17 (3) 253 (50) 236 (47)
Current employment
Employed 61.3 (26.2–172.0) 412 (69) 13 (3) 209 (51) 190 (46)
Not employed 48.0 (25.4–123.0) 173 (29) 5 (3) 85 (49) 83 (48)
Cigarette smoking
Never 56.8 (25.6–157.5) 352 (59) 13 (4) 175 (50) 164 (47)
Former 51.8 (28.4–121.0) 101 (17) 4 (4) 53 (52) 44 (44)
Current 55.1 (26.0–170.5) 148 (25) 2 (1) 77 (52) 69 (47)
Alcohol consumption
Never 54.2 (25.9–156.0) 399 (66) 14 (4) 214 (54) 171 (43)
Former 28.3 (12.5–84.7) 28 (5) 2 (7) 15 (54) 11 (39)
Current  61.0 (31.4–182.0) 174 (29) 3 (1) 76 (44) 95 (55)
Current body mass index (kg/m2)
≤ 20 102.0 (42.1–217.0) 104 (17) 4 (4) 57 (55) 43 (41)
20–25 54.8 (26.8–154.5) 340 (57) 11 (3) 168 (49) 161 (47)
≥ 25 43.2 (19.5–107.0) 157 (26) 4 (3) 80 (51) 73 (47)
Gravidity
0 152.5 (49.0–272.0) 142 (24) 6 (4) 72 (51) 64 (45)
1–2 50.0 (24.8–119.5) 308 (51) 10 (3) 163 (53) 135 (44)
≥ 3 40.7 (21.6–86.2) 151 (25) 3 (2) 70 (46) 78 (52)
Oral contraceptive use (total years)
0 48.2 (24.2–134.5) 208 (35) 4 (2) 87 (42) 117 (56)
< 2 55.2 (24.4–158.0) 169 (28) 7 (4) 98 (58) 64 (38)
3–5 64.6 (29.2–159.0) 106 (18) 4 (4) 55 (52) 47 (44)
> 5 65.0 (37.0–190.0) 116 (19) 3 (3) 65 (56) 48 (41)
Menarche status at accident
Premenarche 130.5 (46.9–251.0) 190 (32) 6 (3) 105 (55) 79 (42)
Postmenarche 44.4 (22.0–96.2) 411 (68) 13 (3) 200 (49) 198 (48)
Chloracne 
Yes 1575.0 (168.0–3180.0) 18 (3) 1 (5) 10 (56) 7 (39)
No 53.7 (25.0–142.0) 583 (97) 18 (3) 295 (51) 270 (46)
aQ1 = 25th percentile; Q3 = 75th percentile. ~20 ng/kg) because previous studies in Seveso
reported an effect at about this level (34).
We performed statistical analyses using
STATA 6.0 (35). We performed polytomous
logistic regression analysis using endometrio-
sis as the outcome with categories “cases,”
“uncertain,” and “nondiseased.” Effects were
characterized by relative risk ratios (RRRs).
We also present crude and adjusted percent-
ages. The form of the dose–response curve
for the probability that a woman had
endometriosis was investigated using frac-
tional polynomials in logistic regression (36).
Potential confounders and effect modi-
ﬁers were selected from the literature (8) and
included the variables presented in Table 1.
None confounded (changed the TCDD para-
meter estimate by more than 10%) or modi-
fied the TCDD–endometriosis association.
Only age was retained in the ﬁnal models. 
Results
We identified 19 cases out of 601 women
(3.2%): 14 with a surgically confirmed
diagnosis of endometriosis and five who
refused laparoscopy but who had ovarian
endometriosis diagnosed by ultrasound. A
total of 277 women were classiﬁed as nondis-
eased: 238 had neither signs (on examina-
tion) nor symptoms (pain or infertility) of
endometriosis, and 39 had no endometriosis
found at pelvic surgery performed either dur-
ing this study or in the past. The remaining
305 women were uncertain for endometrio-
sis, with 273 of these women having either
signs or symptoms. 
Table 1 displays the relation of various
potential covariates with exposure and dis-
ease status. Most women (80%) were ≥ 30
years of age at follow-up (at least 10 years of
age in 1976); approximately two-thirds of
the women in the cohort were postmenar-
cheal at the time of the accident. Serum
TCDD levels tended to be higher in the
women who were < 10 years old at the time
of the accident and in women who lived in
zone A. Higher levels were also found in
women who were premenarcheal at the time
of the accident, never married, nulligravid,
and of lower current body mass; however,
these women were also younger. 
The distribution of TCDD for all
women and for women classiﬁed by disease
status is presented in Figure 1. The overall
median serum TCDD level was 54.9 ppt
with a range of 2.5–17,300 ppt. The median
serum TCDD level for cases was 77.3 ppt;
for nondiseased was 61.0 ppt; and for the
uncertain group was 49.0 ppt. The TCDD
levels for cases and nondiseased overlapped
at the tails of the cumulative distribution,
but cases had higher TCDD levels in the
middle of the distribution. The uncertain
group (mean = 36.1 years, SD = 7.9) was
younger than cases (mean = 37.6 years, SD =
8.2) and the nondiseased group (mean =
37.8 years, SD = 8.1; p = 0.04). 
Table 2 shows the crude and age-
adjusted frequencies of disease category by
TCDD exposure. The adjusted percentages
are the rates predicted by polytomous regres-
sion for a woman with the mean age of 37
years. Although the adjusted percentage of
cases increased from 1.7% for women with
≤ 20.0 ppt serum TCDD to 4.6% for those
with > 100 ppt, the percentage of nondis-
eased women also increased with exposure
levels. Compared to the lowest dose group,
the RRR of the moderate dose group is 1.2
(90% CI = 0.3–4.5) and the RRR of the
highest dose group is 2.1 (90% CI =
0.5–8.0). The test for trend for the cases-to-
nondiseased ratio (scoring categories as 1, 2,
3) was nonsigniﬁcant (p = 0.25). The test for
trend with continuous log TCDD in the
polytomous model was also nonsignificant
(p = 0.84). Fractional polynomials in logistic
regression showed no indication of increas-
ing relative risk with log TCDD.
When we moved the women with either
signs or symptoms to the nondiseased group,
the RRRs for cases relative to the new
nondiseased group were 1.6 (90% CI,
0.4–5.9) for the 20.1–100 ppt group and
2.8 (90% CI, 0.7–10.3) for the > 100 ppt
group. The RRRs for the uncertain group
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Figure 1. Distribution of serum TCDD. (A) Cases (n
= 19), median (range), 77.3 (9.6–686). (B) Uncertain
(n = 305), median (range), 49 (2.5–9,140). (C)
Nondiseased (n = 277), median (range), 61
(2.5–17,300). (D) Total (n = 601), median (range),
54.9 (2.5–17,300). (E) Cumulative distribution,
cases (solid line) and nondiseased (dashed line). 
Table 2. Crude and age-adjusted frequencies and age-adjusted RRR of TCDD exposure and endometriosis
disease classiﬁcation.
TCDD (ppt)
Disease classiﬁcation ≤ 20.0 (n = 111) 20.1–100 (n = 285) > 100 (n = 205)
Cases
Unadjusted frequency (n) 1.8% (2) 2.8% (8) 4.4% (9)
Adjusted frequency 1.7% 2.7% 4.6%
RRR (90% CI) 1.0 (referent) 1.2 (0.3–4.5) 2.1 (0.5–8.0)
Uncertain
Unadjusted frequency (n) 60.4% (67) 47.4% (135) 50.2% (103)
Adjusted frequency 61.8% 48.3% 48.0%
RRR (90% CI) 1.0 (referent) 0.6 (0.4–0.9) 0.6 (0.4–0.9)
Nondiseased
Unadjusted frequency (n) 37.8% (42) 49.8% (142) 45.4% (93)
Adjusted frequency 36.5% 49.0% 47.3%
RRR (90% CI) 1.0 (referent) 1.0 (referent) 1.0 (referent)were now closer to 1.0. The tests for trend
remained nonsignificant (p = 0.15 for
TCDD categories; p = 0.55 for continuous
log TCDD). 
When we compared the cases with only
the portion of the nondiseased group who
had had pelvic surgery (n = 39), the RRRs
were 0.7 (90% CI, 0.2–3.4) for the
20.1–100 ppt group and 2.3 (90% CI,
0.4–11.3) for the > 100 ppt group. The tests
for trend remained nonsigniﬁcant (p = 0.29
for TCDD categories; p = 0.99 for continu-
ous log TCDD). In addition, when we com-
pared only the 14 surgically conﬁrmed cases
with the 39 surgically confirmed nondis-
eased, the RRRs were 1.1 (90% CI =
0.2–7.8) for the 20.1–100 ppt group and
3.6 (90% CI = 0.5–27.0) for the >100 ppt
group. The tests for trend remained non-
significant (p = 0.14 for TCDD categories;
p = 0.83 for continuous log TCDD).
Discussion
The Seveso Women’s Health Study is the ﬁrst
study to investigate the relation between
TCDD exposure and endometriosis in a large
population of women with a wide range of
exposure. We found that women with serum
TCDD levels of 100 ppt or higher had a dou-
bled but statistically nonsignificant risk for
endometriosis. There was also no evidence of
a dose–response relationship. Our results are
consistent with the nonsigniﬁcant odds ratio
of 4.3 associated with serum levels > 100 ppt
TEQ recently reported in a Belgian case–con-
trol study of infertile women (17).
Our study has some important limita-
tions, the most notable of which were the
limited power due to the small number of
women with endometriosis and our inability
to perform laparoscopy on every woman and
thereby to determine deﬁnitively the disease
status for the entire cohort. We conservatively
chose to identify cases based only on women
who had endometriosis identiﬁed by surgery
or ultrasound. Although 34 women were
offered laparoscopy during the study based on
appropriate medical criteria, only nine
accepted. Therefore, we may have missed
cases of endometriosis among the portion of
women in the uncertain or nondiseased
groups who had not had surgery or ovarian
endometriosis (diagnosable by ultrasound).
This misclassiﬁcation would lead to an under-
estimate of the risk, given that it is unlikely
that there was differential disease misclassiﬁca-
tion; neither the investigators who made the
diagnoses nor the interviewers or respondents
knew the TCDD levels, the CDC laboratory
had no information about disease, and the
interviewers and respondents were unaware of
study hypotheses. 
This study may have underestimated the
effects of TCDD in that the group that was
most heavily exposed, the youngest women,
may have been underrepresented. For exam-
ple, for cultural reasons we were unable to
examine women who had never been sexually
active, and they were more likely to be
younger. In addition, because endometriosis
appears during the reproductive years,
younger women would have less of an oppor-
tunity for disease diagnosis. Although we
controlled for age in the analysis, the possibil-
ity of residual confounding by age remains.
One of the strengths of this study is that
use of sera stored from the time of the acci-
dent allowed us to have a direct measure of
an individual’s TCDD level to correlate with
the disease end point. As part of the SWHS,
we were able to analyze these sera for TCDD
for the first time on a large segment of the
Seveso cohort. We chose as our deﬁnition of
low exposure ≤ 20 ppt, based on values from
pooled samples taken from women living in
an unexposed area of Italy in 1976. These
serum levels are higher than current back-
ground levels (< 10 ppt) (37). We did not
measure levels of other dioxin-like com-
pounds (PCDDs, PCDFs, PCBs) that might
have resulted from background exposure in
1976. Because the exposure from the Seveso
explosion was specific to TCDD, the TEQ
in this cohort is likely be dominated by their
exposure to TCDD. However, if the cohort
had substantial levels of other dioxin-like
compounds due to background exposure
and the potential effect derived from total
TEQ, the relative difference across TCDD
exposure groups would have been attenu-
ated. Nevertheless, a larger number of
women with less exposure would not have
changed our conclusion, given that the
prevalence of endometriosis in the ≤ 20 ppt
group was already very low (1.8%). 
In summary, we found a doubled, non-
significant, risk for endometriosis among
women with serum TCDD levels of ≥ 100
ppt. To eliminate the possibility of exposure
misclassiﬁcation, future studies should deter-
mine whether there was substantial exposure to
other PCDDs, PCDFs, and dioxin-like PCBs
in this population. Finally, a more deﬁnitive
study of endometriosis in the Seveso cohort
should be conducted when a noninvasive bio-
marker for endometriosis is developed that can
use the blood samples recently collected from
this cohort. This would reduce the potential
disease misclassiﬁcation inherent in a popula-
tion-based cohort study of endometriosis.
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